Abstract | BACKGROUND:
Necrobiosis lipoidica is a rare granulomatous noninfectious skin disease. Treatment of this chronic debilitating disease is of importance because ulceration of the plaques may induce important psychological and physical morbidity. OBJECTIVE: PATIENTS AND METHODS: Weekly injections of intralesional infliximab for 3 weeks were followed by a 1-week treatment interruption. This treatment schedule was repeated thrice. RESULTS: Two patients who benefitted from complete treatment experienced almost complete remission for up to 18 months. The third patient, who had treatment interruptions, showed partial improvement. No serious side effects were noticed, although the injections caused pain. CONCLUSIONS:
|
Authors | C Barde, E Laffitte, A Campanelli, J-H Saurat, A-M Thielen |
Journal | Dermatology (Basel, Switzerland)
(Dermatology)
Vol. 222
Issue 3
Pg. 212-6
( 2011)
ISSN: 1421-9832 [Electronic] Switzerland |
PMID | 21625077
(Publication Type: Case Reports, Journal Article)
|
Copyright | Copyright © 2011 S. Karger AG, Basel. |
Chemical References |
- Antibodies, Monoclonal
- Dermatologic Agents
- Infliximab
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(administration & dosage)
- Dermatologic Agents
(administration & dosage)
- Female
- Granuloma
(drug therapy)
- Humans
- Infliximab
- Injections, Intralesional
- Male
- Necrobiosis Lipoidica
(drug therapy)
- Treatment Outcome
- Young Adult
|